Literature DB >> 29087384

PARPi focus the spotlight on replication fork protection in cancer.

Katharina Schlacher1.   

Abstract

PARP inhibitors (PARPi) kill BRCA1/2-mutated cancers, which become resistant when DNA repair functions are restored. Now, MUS81 nuclease inhibition due to EZH2 downregulation is found to restore DNA replication fork protection but not repair, leading to PARPi-resistance in mutant BRCA2 cells and patients. This challenges the DNA repair dominance in synthetic lethality.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29087384     DOI： 10.1038/ncb3638

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN： 1465-7392            Impact factor:   28.824


  13 in total

1.  RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks.

Authors:  Huzefa Dungrawala; Kamakoti P Bhat; Rémy Le Meur; Walter J Chazin; Xia Ding; Shyam K Sharan; Sarah R Wessel; Aditya A Sathe; Runxiang Zhao; David Cortez
Journal:  Mol Cell       Date:  2017-07-20       Impact factor: 17.970

2.  Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1.

Authors:  Songmin Ying; Freddie C Hamdy; Thomas Helleday
Journal:  Cancer Res       Date:  2012-03-23       Impact factor: 12.701

3.  Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11.

Authors:  Katharina Schlacher; Nicole Christ; Nicolas Siaud; Akinori Egashira; Hong Wu; Maria Jasin
Journal:  Cell       Date:  2011-05-13       Impact factor: 41.582

4.  53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.

Authors:  Samuel F Bunting; Elsa Callén; Nancy Wong; Hua-Tang Chen; Federica Polato; Amanda Gunn; Anne Bothmer; Niklas Feldhahn; Oscar Fernandez-Capetillo; Liu Cao; Xiaoling Xu; Chu-Xia Deng; Toren Finkel; Michel Nussenzweig; Jeremy M Stark; André Nussenzweig
Journal:  Cell       Date:  2010-04-01       Impact factor: 41.582

5.  EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.

Authors:  Beatrice Rondinelli; Ewa Gogola; Hatice Yücel; Alexandra A Duarte; Marieke van de Ven; Roxanne van der Sluijs; Panagiotis A Konstantinopoulos; Jos Jonkers; Raphaël Ceccaldi; Sven Rottenberg; Alan D D'Andrea
Journal:  Nat Cell Biol       Date:  2017-10-16       Impact factor: 28.824

6.  A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent of Homologous Recombination.

Authors:  Anderson T Wang; Taeho Kim; John E Wagner; Brooke A Conti; Francis P Lach; Athena L Huang; Henrik Molina; Erica M Sanborn; Heather Zierhut; Belinda K Cornes; Avinash Abhyankar; Carrie Sougnez; Stacey B Gabriel; Arleen D Auerbach; Stephen C Kowalczykowski; Agata Smogorzewska
Journal:  Mol Cell       Date:  2015-08-06       Impact factor: 17.970

7.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.

Authors:  Wataru Sakai; Elizabeth M Swisher; Beth Y Karlan; Mukesh K Agarwal; Jake Higgins; Cynthia Friedman; Emily Villegas; Céline Jacquemont; Daniel J Farrugia; Fergus J Couch; Nicole Urban; Toshiyasu Taniguchi
Journal:  Nature       Date:  2008-02-10       Impact factor: 49.962

Review 8.  The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.

Authors:  Thomas Helleday
Journal:  Mol Oncol       Date:  2011-07-22       Impact factor: 7.449

9.  Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition.

Authors:  Matteo Berti; Arnab Ray Chaudhuri; Saravanabhavan Thangavel; Shivasankari Gomathinayagam; Sasa Kenig; Marko Vujanovic; Federico Odreman; Timo Glatter; Simona Graziano; Ramiro Mendoza-Maldonado; Francesca Marino; Bojana Lucic; Valentina Biasin; Matthias Gstaiger; Ruedi Aebersold; Julia M Sidorova; Raymond J Monnat; Massimo Lopes; Alessandro Vindigni
Journal:  Nat Struct Mol Biol       Date:  2013-02-10       Impact factor: 15.369

10.  Replication fork stability confers chemoresistance in BRCA-deficient cells.

Authors:  Arnab Ray Chaudhuri; Elsa Callen; Xia Ding; Ewa Gogola; Alexandra A Duarte; Ji-Eun Lee; Nancy Wong; Vanessa Lafarga; Jennifer A Calvo; Nicholas J Panzarino; Sam John; Amanda Day; Anna Vidal Crespo; Binghui Shen; Linda M Starnes; Julian R de Ruiter; Jeremy A Daniel; Panagiotis A Konstantinopoulos; David Cortez; Sharon B Cantor; Oscar Fernandez-Capetillo; Kai Ge; Jos Jonkers; Sven Rottenberg; Shyam K Sharan; André Nussenzweig
Journal:  Nature       Date:  2016-07-21       Impact factor: 49.962
View more
  13 in total

Review 1.  Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.

Authors:  Brittany Haynes; Junko Murai; Jung-Min Lee
Journal:  Cancer Treat Rev       Date:  2018-09-11       Impact factor: 12.111

Review 2.  The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.

Authors:  Melissa M Pham; Emily Hinchcliff; Monica Avila; Shannon N Westin
Journal:  Cancer J       Date:  2021 Nov-Dec 01       Impact factor: 2.074

3.  A game of substrates: replication fork remodeling and its roles in genome stability and chemo-resistance.

Authors:  Julia Sidorova
Journal:  Cell Stress       Date:  2017-12-05

Review 4.  PARP inhibitor resistance: the underlying mechanisms and clinical implications.

Authors:  He Li; Zhao-Yi Liu; Nayiyuan Wu; Yong-Chang Chen; Quan Cheng; Jing Wang
Journal:  Mol Cancer       Date:  2020-06-20       Impact factor: 27.401

5.  Clinical protein science in translational medicine targeting malignant melanoma.

Authors:  Jeovanis Gil; Lazaro Hiram Betancourt; Indira Pla; Aniel Sanchez; Roger Appelqvist; Tasso Miliotis; Magdalena Kuras; Henriette Oskolas; Yonghyo Kim; Zsolt Horvath; Jonatan Eriksson; Ethan Berge; Elisabeth Burestedt; Göran Jönsson; Bo Baldetorp; Christian Ingvar; Håkan Olsson; Lotta Lundgren; Peter Horvatovich; Jimmy Rodriguez Murillo; Yutaka Sugihara; Charlotte Welinder; Elisabet Wieslander; Boram Lee; Henrik Lindberg; Krzysztof Pawłowski; Ho Jeong Kwon; Viktoria Doma; Jozsef Timar; Sarolta Karpati; A Marcell Szasz; István Balázs Németh; Toshihide Nishimura; Garry Corthals; Melinda Rezeli; Beatrice Knudsen; Johan Malm; György Marko-Varga
Journal:  Cell Biol Toxicol       Date:  2019-03-21       Impact factor: 6.691

6.  PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity.

Authors:  Shiv K Gupta; Emily J Smith; Ann C Mladek; Shulan Tian; Paul A Decker; Sani H Kizilbash; Gaspar J Kitange; Jann N Sarkaria
Journal:  Front Oncol       Date:  2019-01-22       Impact factor: 6.244

Review 7.  Resolvases, Dissolvases, and Helicases in Homologous Recombination: Clearing the Road for Chromosome Segregation.

Authors:  Pedro A San-Segundo; Andrés Clemente-Blanco
Journal:  Genes (Basel)       Date:  2020-01-08       Impact factor: 4.096

8.  A stapled peptide mimetic of the CtIP tetramerization motif interferes with double-strand break repair and replication fork protection.

Authors:  Anika Kuster; Nour L Mozaffari; Oliver J Wilkinson; Jessica L Wojtaszek; Christina Zurfluh; Sara Przetocka; Dawid Zyla; Christine von Aesch; Mark S Dillingham; R Scott Williams; Alessandro A Sartori
Journal:  Sci Adv       Date:  2021-02-19       Impact factor: 14.136

9.  Rare variants in Fanconi anemia genes are enriched in acute myeloid leukemia.

Authors:  Kyaw Ze Ya Maung; Paul J Leo; Mahmoud Bassal; Debora A Casolari; James X Gray; Sarah C Bray; Stephen Pederson; Deepak Singhal; Saumya E Samaraweera; Tran Nguyen; Gökhan Cildir; Mhairi Marshall; Adam Ewing; Emma L Duncan; Matthew A Brown; Russell Saal; Vinay Tergaonkar; Luen Bik To; Paula Marlton; Devinder Gill; Ian Lewis; Andrew J Deans; Anna L Brown; Richard J D'Andrea; Thomas J Gonda
Journal:  Blood Cancer J       Date:  2018-06-01       Impact factor: 11.037

10.  SMC5/6 acts jointly with Fanconi anemia factors to support DNA repair and genome stability.

Authors:  Francesco Rossi; Anne Helbling-Leclerc; Ryotaro Kawasumi; Nanda Kumar Jegadesan; Xinlin Xu; Pierre Devulder; Takuya Abe; Minoru Takata; Dongyi Xu; Filippo Rosselli; Dana Branzei
Journal:  EMBO Rep       Date:  2019-12-23       Impact factor: 8.807
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.